QURE

uniQure NV

22.72

Oct 20 • 3:59 PM ET +0.51 (2.32%)

22.50

Aftermarket • 7:30 PM ET -0.22 (-0.95%)

Healthcare Biotechnology Netherlands Small NASD

Peers: RGNX SRPT PTCT MGTX TSHA RARE BMRN SLDB VYGR CRSP

| Held by: XBI VXF IBB JGRO SCHA VHT PTH ITOT KOMP LABU

Scroll to Statements

Index	-
Market Cap	1.58B
Enterprise Value	1.32B
Income	-252.21M
Sales	18.67M
Book/sh	4.67
Cash/sh	11.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	221
IPO	Feb 05, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	84.39
P/B	4.86
P/C	1.94
P/FCF	-
EV/EBITDA	-
EV/Sales	70.57
Quick Ratio	10.01
Current Ratio	10.01
Debt/Eq	1.70
LT Debt/Eq	1.69
Option/Short	Yes / Yes

EPS (ttm)	-4.05
EPS next Y	-3.02
EPS next Q	-0.92
EPS this Y	-12.03%
EPS next Y	22.14%
EPS next 5Y	30.27%
EPS past 3/5Y	-8.45% -4.24%
Sales past 3/5Y	-46.73% -15.57%
EPS Y/Y TTM	-3.25%
Sales Y/Y TTM	30.24%
EPS Q/Q	-77.81%
Sales Q/Q	11.00%
Earnings	Jul 29 BMO
EPS/Sales Surpr.	-48.36% 7.19%

Insider Own	7.08%
Insider Trans	-8.11%
Inst Own	92.14%
Inst Trans	4.98%
ROA	-32.13%
ROE	-157.61%
ROIC	-28.88%
Gross Margin	15.02%
Oper. Margin	-1093.18%
Profit Margin	-1350.73%
SMA20	-12.86%
SMA50	-40.76%
SMA200	-23.32%
Trades

Shs Outstand	69.33M
Shs Float	64.46M
Short Float	13.52%
Short Ratio	4.27
Short Interest	8.72M
52W High	71.50 -68.23%
52W Low	8.73 160.19%
Volatility	5.76% 7.00%
ATR (14)	1.96
RSI (14)	27.42
Beta	1.15
Rel Volume	0.69
Avg Volume	2.04M
Volume	1,417,981

Perf Week	6.74%
Perf Month	-48.74%
Perf Quarter	-43.75%
Perf Half Y	30.17%
Perf YTD	-5.08%
Perf Year	-64.46%
Perf 3Y	267.56%
Perf 5Y	-20.21%
Perf 10Y	209.47%
Recom	1.29
Target Price	59.75
Prev Close	22.20
Price	22.72
Change %	2.32%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-05-26	Downgrade	Barclays	Overweight → Equal Weight	$28
Sep-02-26	Resumed	William Blair	Outperform
Jul-30-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$65
Jun-18-26	Upgrade	Barclays	Equal Weight → Overweight	$65
Jun-17-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$61
Mar-11-26	Upgrade	Mizuho	Neutral → Outperform	$35
Mar-09-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$60
Mar-09-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$35
Mar-03-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$15
Mar-03-26	Downgrade	Mizuho	Outperform → Neutral	$12
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11
Mar-02-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$9
Feb-24-26	Initiated	Wolfe Research	Peer Perform
Jan-28-26	Initiated	Barclays	Equal Weight	$31
Nov-04-25	Downgrade	William Blair	Outperform → Mkt Perform
Aug-14-25	Upgrade	Mizuho	Neutral → Outperform	$30
Apr-01-25	Resumed	Chardan Capital Markets	Buy	$38
Dec-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Oct-10-24	Resumed	Raymond James	Outperform	$20
Feb-29-24	Downgrade	Goldman	Buy → Neutral	$8

Show Previous Ratings

Sep-29-26 06:08PM	QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntingtons Data Spooks Investors Despite Stronger Three-Year Filing Data (Stocktwits) -37.33%
09:31AM	uniQure Shares Fall 64% After 48-Month AMT-130 Huntington's Disease Trial Update (InvestorsHub)
09:30AM	ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update (InvestorsHub)
09:26AM	UniQure Insists Huntington's Drug Is Still on Track as Stock Plunges 48% (Barrons.com)
08:58AM	QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntingtons Disease Data Heres What Investors Need To Know (Stocktwits)
07:56AM	Loading…
07:56AM	uniQure plunges 65% as 48-month Huntingtons gene therapy data misses key stat (Investing.com)
07:12AM	uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease Showing Continued Slowing of Disease Progression (GlobeNewswire)
Sep-27-26 11:31PM	Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week Here Are The Stocks And Readouts To Watch (Stocktwits)
Sep-16-26 05:30AM	Trump Administration Shift Puts This Corner of Biotech Back in Favor (The Wall Street Journal)
Sep-02-26 06:35PM	QURE Stock Fades After AMT-130 filing But William Blair Sees 58% Upside (Stocktwits)
09:54AM	Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls (The Fly)
07:05AM	uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease (GlobeNewswire)
Jul-30-26 09:38AM	Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls (The Fly) +5.29%
Jul-29-26 05:02PM	uniQure NV (QURE) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Operational Challenges (GuruFocus.com) +9.30%
11:49AM	AdCom expected for uniQures Huntingtons gene therapy, chief medical officer says (Pharmaceutical Technology)
07:17AM	Loading…
07:17AM	UniQure: Q2 Earnings Snapshot (Associated Press)
07:05AM	uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update (GlobeNewswire)
Jul-22-26 07:05AM	uniQure to Announce Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-08-26 10:15AM	3 Biotech Stocks to Watch Before Wall Street Catches On (InvestorPlace) +5.02%
Jun-29-26 07:53PM	XBI Ignored The Market's Downturn (Trefis)
Jun-25-26 04:10PM	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-23-26 09:13PM	uniQure Announces Pricing of Upsized $225 Million Public Offering (GlobeNewswire) +10.48%
Jun-22-26 04:01PM	uniQure Announces $150 Million Proposed Public Offering (GlobeNewswire)
Jun-19-26 08:24AM	QURE Was Just the Beginning: 5 Biotech Catalysts Im Watching Now (InvestorPlace)
07:05AM	uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (GlobeNewswire)
Jun-18-26 10:57AM	UniQure to seek approval of Huntingtons gene therapy after FDA U-turn (Pharmaceutical Technology)
09:35AM	SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls (The Fly)
Jun-17-26 04:48PM	?? Under the Radar: uniQure Shares Surge After FDA's Reversal on Gene Therapy (The Wall Street Journal) +78.44%
10:10AM	This Biotech Stock Is Surging 66% on Surprise Good News From FDA (Barrons.com)
09:08AM	QURE Stock Surges Over 70% After FDA Softens Stance On Huntingtons Disease Gene Therapy (Stocktwits)
08:56AM	Loading…
08:56AM	ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value (InvestorsHub)
08:55AM	uniQure Positioned for Gains After FDA Supports Accelerated Approval Path for AMT-130 (InvestorsHub)
07:05AM	uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease (GlobeNewswire)
May-20-26 05:30AM	Biotech Investors Are Tuning Out the MAHA Chaos (The Wall Street Journal)
May-06-26 06:48PM	Oncolytics Biotech Reports Data in Colorectal Cancer Study (IPO-Edge.com) +7.84% +5.83%
May-05-26 07:21AM	UniQure: Q1 Earnings Snapshot (Associated Press)
07:05AM	uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates (GlobeNewswire)
Apr-30-26 07:05AM	uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease (GlobeNewswire) +19.25%
Apr-28-26 07:05AM	uniQure to Announce First Quarter 2026 Financial Results (GlobeNewswire)
Mar-20-26 03:23AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire) +5.44%
Mar-10-26 08:17AM	uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy? (Benzinga)
Mar-09-26 04:37PM	This biotech's stock soared after a 'polarizing' FDA official is stepping down (MarketWatch) +26.07%
01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga)
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
11:17AM	uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts (24/7 Wall St.)
08:23AM	uniQure stock surges 36% on FDA officials departure (Investing.com)
07:01AM	Why Is uniQure Stock Skyrocketing Monday? (Benzinga)
05:28AM	Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike-Hims & Hers, Ovintiv, Uniqure In Focus (Benzinga)
Mar-06-26 07:13PM	FDA Vaccine Chief Vinay Prasad Set to Leave Post Next Month (Bloomberg) +33.99%
09:57AM	QURE Stock Crashes 32% in a Week: Here's What You Should Know (Zacks)
Mar-05-26 06:01PM	Federal Health Officials Attack Rare-Disease Drug, Say Company Lied (The Wall Street Journal) +17.81%
12:11PM	FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial (Benzinga)
Mar-04-26 09:58AM	What's Going On With uniQure Stock Wednesday? (Benzinga)
09:35AM	uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-03-26 11:38AM	uniQure downgraded after FDA backs sham-controlled trial for Huntingtons therapy (Investing.com) -14.00%
09:33AM	MongoDB downgraded, Block upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Block, CrowdStrike, Fortinet, MongoDB, Mosaic, Palo Alto Networks, Unity Software, and More (24/7 Wall St.)
Mar-02-26 04:37PM	Stocks Recover as Iran War Pushes Energy and Defense Stocks Higher (Barchart) -32.82%
04:28PM	Uniqure Plummets By A Third After Realizing 'The Worst Case Scenario' For Its Gene Therapy (Investor's Business Daily)
02:01PM	uniQure NV (QURE) Q4 2025 Earnings Call Highlights: Breakthroughs and Challenges in Gene Therapy (GuruFocus.com)
12:57PM	FDA tells uniQure to conduct another study of Huntingtons gene therapy (Clinical Trials Arena)
12:33PM	uniQure N.V. Q4 2025 Earnings Call Summary (Moby)
11:37AM	UniQure Stock Drops 36% After Earnings. Bad News From the FDA Gets Even Worse. (Barrons.com)
11:19AM	Markets Rebound After Initial Selloff Triggered by Middle East Tensions (Barchart)
10:37AM	uniQure Q4 Earnings Call Highlights (MarketBeat)
08:58AM	Uniqure Plummets More Than 40% On Another Twist In Its Gene Therapy Saga (Investor's Business Daily)
08:51AM	uniQure Stock Plunges 40% After FDA Shocker (Benzinga)
08:20AM	uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	UniQure: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces 2025 Financial Results and Provides Recent Company Updates (GlobeNewswire)
07:00AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Feb-28-26 02:21AM	Wolfe Research Initiates Coverage of UniQure (QURE) With a Peer Perform Rating (Insider Monkey)
Feb-27-26 12:49AM	QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? (New feeds test provider finance) -8.68%
Feb-26-26 04:06PM	Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug (Investor's Business Daily) -31.18%
09:55AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-23-26 07:05AM	uniQure to Announce 2025 Financial Results (GlobeNewswire)
Feb-18-26 09:00AM	uniQure N.V. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 13, 2026 to Discuss Your Rights - QURE (PR Newswire) +7.72%
Feb-14-26 01:28AM	UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity (Insider Monkey)
Feb-13-26 01:11AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire) -8.36%
Feb-12-26 08:00AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights QURE (Business Wire) -7.22%
Feb-06-26 01:58PM	Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch (Benzinga)
07:05AM	uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease (GlobeNewswire)
Feb-02-26 09:35AM	uniQure (QURE) Navigates Gene Therapy Development as Investors Weigh Long-Term Potential (Insider Monkey) +8.71%
Jan-20-26 09:01AM	Here's Why uniQure (QURE) Fell in Q3 (Insider Monkey)
Jan-12-26 10:11AM	Is UniQure (QURE) One of the Promising Stocks to Buy Under $50? (Insider Monkey) -9.00%
Jan-09-26 01:14PM	uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT-130 Approval Pathway (Benzinga) +9.37%
07:05AM	uniQure Announces Type A Meeting Scheduled with FDA (GlobeNewswire)
Dec-21-25 09:56AM	What Do Analysts Think About UniQure (QURE)? (Insider Monkey)
Dec-15-25 11:11PM	UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington's Data Spurs Mizuho Downgrade and Delayed Launch (Insider Monkey) +7.15%
Dec-04-25 12:18PM	uniQure N.V. (QURE): A Bear Case Theory (Insider Monkey) -10.75%
10:02AM	UniQure Plummets, Again, As FDA Indicates It Will Reject Huntington's Gene Therapy (Investor's Business Daily)
07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Nov-25-25 08:39AM	William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty (Insider Monkey)
Nov-19-25 08:16AM	Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3 (Insider Monkey) -5.92%
Nov-17-25 12:15PM	Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA (Insider Monkey)
Nov-12-25 07:00AM	uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences (Insider Monkey)
Nov-10-25 04:01PM	uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges (GuruFocus.com) -5.90% +17.93%
08:15AM	uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:14AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapusta Matthew C	CEO, Managing Director	Jul 02 '26	Option Exercise	19.39	21,082	408,780	540,309	Jul 07 04:47 PM
Kapusta Matthew C	CEO, Managing Director	Jul 02 '26	Sale	45.16	21,082	952,051	519,227	Jul 07 04:47 PM
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Option Exercise	5.59	10,000	55,900	178,235	Jul 02 04:59 PM
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Sale	46.42	30,000	1,392,600	148,235	Jul 02 04:59 PM
Kaye Jack	Director	Jun 30 '26	Option Exercise	23.44	21,167	496,230	43,056	Jul 02 04:54 PM
Kaye Jack	Director	Jun 30 '26	Sale	46.44	21,167	983,030	25,996	Jul 02 04:54 PM
Kapusta Matthew C	Officer	Jul 02 '26	Proposed Sale	45.15	21,082	951,932		Jul 02 04:00 PM
Abi-Saab Walid	Chief Medical Officer	Jun 26 '26	Sale	46.86	1,434	67,197	168,235	Jun 30 05:06 PM
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Proposed Sale	46.42	30,000	1,392,643		Jun 30 04:01 PM
Kaye Jack	Director	Jun 30 '26	Proposed Sale	46.44	21,167	983,033		Jun 30 04:00 PM
Kapusta Matthew C	CEO, Managing Director	Jun 25 '26	Option Exercise	31.71	28,716	910,584	547,943	Jun 26 05:15 PM
Kapusta Matthew C	CEO, Managing Director	Jun 24 '26	Option Exercise	31.71	4,128	130,899	525,923	Jun 26 05:15 PM
Kapusta Matthew C	CEO, Managing Director	Jun 25 '26	Sale	50.02	28,716	1,436,374	519,227	Jun 26 05:15 PM
Kapusta Matthew C	CEO, Managing Director	Jun 24 '26	Sale	50.00	6,696	334,800	519,227	Jun 26 05:15 PM
Abi-Saab Walid	Chief Medical Officer	Jun 26 '26	Proposed Sale	46.86	1,434	67,197		Jun 26 04:06 PM
Kapusta Matthew C	Officer	Jun 25 '26	Proposed Sale	50.02	28,716	1,436,305		Jun 25 04:00 PM
Kapusta Matthew C	Officer	Jun 24 '26	Proposed Sale	50.00	6,696	334,800		Jun 24 04:01 PM
Kapusta Matthew C	CEO, Managing Director	Jun 17 '26	Option Exercise	19.39	62,581	1,213,446	723,239	Jun 22 08:31 AM
Kapusta Matthew C	CEO, Managing Director	Jun 18 '26	Option Exercise	31.71	4,656	147,642	563,466	Jun 22 08:31 AM
Kapusta Matthew C	CEO, Managing Director	Jun 17 '26	Sale	44.32	164,429	7,288,062	558,810	Jun 22 08:31 AM
Kapusta Matthew C	CEO, Managing Director	Jun 18 '26	Sale	50.00	41,671	2,083,550	521,795	Jun 22 08:31 AM
Balachandran Madhavan	Director	Jun 17 '26	Option Exercise	24.97	11,685	291,807	54,939	Jun 22 08:05 AM
Balachandran Madhavan	Director	Jun 17 '26	Sale	45.06	11,685	526,485	43,254	Jun 22 08:05 AM
Kaye Jack	Director	Jun 17 '26	Option Exercise	31.71	5,295	167,904	31,291	Jun 22 07:54 AM
Kaye Jack	Director	Jun 17 '26	Sale	42.57	5,295	225,408	25,996	Jun 22 07:54 AM
Kapusta Matthew C	Officer	Jun 18 '26	Proposed Sale	46.38	41,671	1,932,516		Jun 18 05:57 PM
Kapusta Matthew C	Officer	Jun 17 '26	Proposed Sale	43.00	164,429	7,070,447		Jun 17 08:07 PM
Balachandran Madhavan	Director	Jun 15 '26	Option Exercise	8.49	10,000	84,900	53,254	Jun 17 05:02 PM
Balachandran Madhavan	Director	Jun 15 '26	Sale	27.85	10,000	278,500	43,254	Jun 17 05:02 PM
Potts Jeannette	Chief Legal Officer	Jun 15 '26	Sale	27.67	5,237	144,908	133,246	Jun 17 04:56 PM
Kaye Jack	Director	Jun 17 '26	Proposed Sale	42.57	5,295	225,393		Jun 17 04:34 PM
Balachandran Madhavan	Director	Jun 17 '26	Proposed Sale	45.05	11,685	526,463		Jun 17 04:03 PM
Potts Jeannette	Officer	Jun 15 '26	Proposed Sale	27.67	5,237	144,886		Jun 15 04:00 PM
Meek David D.	Director	Jun 11 '26	Sale	27.06	1,993	53,931	39,747	Jun 12 06:13 PM
Gut Robert	Director	Jun 10 '26	Option Exercise	16.04	2,645	42,426	34,987	Jun 12 06:04 PM
Gut Robert	Director	Jun 10 '26	Sale	26.05	7,552	196,720	27,435	Jun 12 06:04 PM
Gut Robert	Director	Jun 11 '26	Sale	27.06	2,726	73,766	32,259	Jun 12 06:04 PM
O'Keefe Kylie	Chief Customer & Strat Officer	Jun 11 '26	Sale	27.06	15,936	431,228	108,864	Jun 12 05:55 PM
Springhorn Jeremy P.	Director	Jun 11 '26	Sale	27.06	1,993	53,931	43,251	Jun 12 05:45 PM
POST LEONARD E	Director	Jun 11 '26	Sale	27.06	1,993	53,931	35,494	Jun 12 05:38 PM
Kaye Jack	Director	Jun 11 '26	Sale	27.06	1,993	53,931	25,996	Jun 12 05:30 PM
Jacques Rachelle Suzanne	Director	Jun 11 '26	Sale	27.06	1,993	53,931	33,903	Jun 12 05:15 PM
Balachandran Madhavan	Director	Jun 11 '26	Sale	27.06	1,993	53,931	43,254	Jun 12 05:08 PM
O'Keefe Kylie	Officer	Jun 11 '26	Proposed Sale	27.06	15,936	431,290		Jun 11 04:39 PM
Balachandran Madhavan	Director	Jun 11 '26	Proposed Sale	27.06	11,993	324,578		Jun 11 04:29 PM
Gut Robert	Director	Jun 11 '26	Proposed Sale	27.06	2,726	73,776		Jun 11 04:25 PM
Springhorn Jeremy P.	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:23 PM
Jacques Rachelle Suzanne	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:22 PM
POST LEONARD E	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:20 PM
Meek David D.	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:19 PM
Kaye Jack	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:18 PM
Gut Robert	Director	Jun 10 '26	Proposed Sale	26.05	7,552	196,725		Jun 10 04:00 PM
Kaye Jack	Director	Jun 03 '26	Option Exercise	16.04	2,645	42,426	23,084	Jun 05 04:43 PM
Kaye Jack	Director	Jun 03 '26	Sale	30.01	2,645	79,376	20,439	Jun 05 04:43 PM
Kaye Jack	Director	Jun 03 '26	Proposed Sale	30.01	2,645	79,384		Jun 03 03:58 PM
Abi-Saab Walid	Chief Medical Officer	May 08 '26	Option Exercise	5.59	25,000	139,750	214,669	May 12 04:54 PM
Abi-Saab Walid	Chief Medical Officer	May 08 '26	Sale	25.06	45,000	1,127,500	169,669	May 12 04:54 PM
Abi-Saab Walid	Chief Medical Officer	May 08 '26	Proposed Sale	25.05	45,000	1,127,435		May 08 04:00 PM
Kapusta Matthew C	CEO, Managing Director	Mar 04 '26	Sale	9.06	14,581	132,104	660,658	Mar 06 05:07 PM
Abi-Saab Walid	Chief Medical Officer	Mar 04 '26	Sale	9.06	808	7,320	189,669	Mar 06 04:59 PM
Potts Jeannette	Chief Legal Officer	Mar 04 '26	Sale	9.06	3,412	30,913	138,483	Mar 06 04:35 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 04 '26	Sale	9.06	12,000	108,720	226,581	Mar 06 04:30 PM
Potts Jeannette	Officer	Mar 04 '26	Proposed Sale	9.06	3,412	30,927		Mar 04 04:56 PM
KLEMT CHRISTIAN	Officer	Mar 04 '26	Proposed Sale	9.06	12,000	108,770		Mar 04 04:50 PM
Kapusta Matthew C	Director	Mar 04 '26	Proposed Sale	9.06	14,581	132,165		Mar 04 04:46 PM
Kapusta Matthew C	CEO, Managing Director	Mar 02 '26	Sale	9.95	34,437	342,648	604,639	Mar 04 04:42 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 02 '26	Sale	9.95	12,532	124,693	198,981	Mar 04 04:36 PM
Potts Jeannette	Chief Legal Officer	Mar 02 '26	Sale	9.95	8,578	85,351	106,495	Mar 04 04:31 PM
Abi-Saab Walid	Chief Medical Officer	Mar 02 '26	Sale	9.95	1,660	16,517	148,777	Mar 04 04:25 PM
Kapusta Matthew C	Director	Mar 02 '26	Proposed Sale	9.95	34,437	342,586		Mar 02 05:39 PM
KLEMT CHRISTIAN	Officer	Mar 02 '26	Proposed Sale	9.95	12,832	127,655		Mar 02 05:29 PM
Potts Jeannette	Officer	Mar 02 '26	Proposed Sale	9.95	8,578	85,336		Mar 02 05:23 PM
Kapusta Matthew C	CEO, Managing Director	Feb 25 '26	Sale	23.86	12,378	295,339	639,076	Feb 27 04:49 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 25 '26	Sale	23.86	6,217	148,338	211,513	Feb 27 04:42 PM
Kapusta Matthew C	Director	Feb 25 '26	Proposed Sale	23.86	12,378	295,307		Feb 25 04:07 PM
KLEMT CHRISTIAN	Officer	Feb 25 '26	Proposed Sale	23.86	6,217	148,321		Feb 25 04:01 PM
Gut Robert	Director	Jan 12 '26	Option Exercise	14.08	17,810	250,765	57,955	Jan 14 04:26 PM
Gut Robert	Director	Jan 12 '26	Sale	24.62	25,613	630,483	32,342	Jan 14 04:26 PM
Kaye Jack	Director	Jan 09 '26	Option Exercise	19.39	6,390	123,902	26,829	Jan 12 04:21 PM
Kaye Jack	Director	Jan 09 '26	Sale	27.28	6,390	174,319	20,439	Jan 12 04:21 PM
Gut Robert	Director	Jan 12 '26	Proposed Sale	26.42	25,613	676,695		Jan 12 03:59 PM
Kaye Jack	Director	Jan 09 '26	Proposed Sale	27.28	6,390	174,330		Jan 09 03:59 PM
Gut Robert	Director	Nov 06 '25	Option Exercise	4.57	15,840	72,389	71,579	Nov 10 04:54 PM
Gut Robert	Director	Nov 06 '25	Sale	27.26	31,434	856,881	40,145	Nov 10 04:54 PM
Kaye Jack	Director	Nov 04 '25	Option Exercise	9.88	38,810	383,535	38,249	Nov 06 05:01 PM
Kaye Jack	Director	Nov 04 '25	Sale	30.34	38,810	1,177,517	20,439	Nov 06 05:01 PM
Gut Robert	Director	Nov 06 '25	Proposed Sale	26.06	31,434	819,170		Nov 06 04:13 PM
Kaye Jack	Director	Nov 04 '25	Proposed Sale	34.29	38,810	1,330,794		Nov 04 04:00 PM

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

CEO & Executive DirectorMr. Matthew Craig Kapusta CPA

CFOMr. Christian Klemt

Ph.D.Dr. Jeannette Potts J.D.

Chief Medical OfficerDr. Walid Abi-Saab M.D.

Chairman of Scientific Advisory Board and Managing Director of UniQure-GermanyProf. Hugo Katus

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QURE

uniQure NV

Upgrade your Finviz experience